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CTE, Alzheimer’s disease, progressive supranuclear palsy, 
argyrophilic grain disease, corticobasal degeneration, pri-
mary age-related tauopathy, and parkinsonism dementia 
complex of Guam. The results demonstrated that there 
was good agreement among the neuropathologists who 
reviewed the cases (Cohen’s kappa, 0.67) and even better 
agreement between reviewers and the diagnosis of CTE 
(Cohen’s kappa, 0.78). Based on these results, the panel 
defined the pathognomonic lesion of CTE as an accumula-
tion of abnormal hyperphosphorylated tau (p-tau) in neu-
rons and astroglia distributed around small blood vessels 
at the depths of cortical sulci and in an irregular pattern. 
The group also defined supportive but non-specific p-tau-
immunoreactive features of CTE as: pretangles and NFTs 
affecting superficial layers (layers II–III) of cerebral cortex; 
Abstract Chronic traumatic encephalopathy (CTE) is a 
neurodegeneration characterized by the abnormal accumu-
lation of hyperphosphorylated tau protein within the brain. 
Like many other neurodegenerative conditions, at present, 
CTE can only be definitively diagnosed by post-mortem 
examination of brain tissue. As the first part of a series of 
consensus panels funded by the NINDS/NIBIB to define 
the neuropathological criteria for CTE, preliminary neuro-
pathological criteria were used by 7 neuropathologists to 
blindly evaluate 25 cases of various tauopathies, including 
The members representing TBI/CTE group are listed in the 
Appendix.
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pretangles, NFTs or extracellular tangles in CA2 and pre-
tangles and proximal dendritic swellings in CA4 of the 
hippocampus; neuronal and astrocytic aggregates in sub-
cortical nuclei; thorn-shaped astrocytes at the glial limitans 
of the subpial and periventricular regions; and large grain-
like and dot-like structures. Supportive non-p-tau patholo-
gies include TDP-43 immunoreactive neuronal cytoplas-
mic inclusions and dot-like structures in the hippocampus, 
anteromedial temporal cortex and amygdala. The panel also 
recommended a minimum blocking and staining scheme 
for pathological evaluation and made recommendations 
for future study. This study provides the first step towards 
the development of validated neuropathological criteria 
for CTE and will pave the way towards future clinical and 
mechanistic studies.
Keywords Chronic traumatic encephalopathy · 
Traumatic brain injury · Tauopathy · Brain trauma · 
Neurodegenerative disorders
Introduction
In 1928, the pathologist and medical examiner, Harrison 
Stanford Martland, introduced the term ‘punch-drunk’ to 
describe the clinical features of a distinct neuropsychi-
atric syndrome that affected boxers [26]; a condition that 
later came to be known as ‘dementia pugilistica’ [33]. Case 
reports and small series describing the neuropathologic fea-
tures of the condition appeared in the 1950s and 1960s [3, 
6, 16, 27, 35, 41]. Although the histological techniques var-
ied, the most common pathological findings were cerebral 
atrophy, neuronal loss, gliosis and argyrophilic neurofibril-
lary tangles. In the seminal 1973 monograph on the clin-
icopathological features of dementia pugilistica in 15 for-
mer male boxers, Corsellis, Bruton, and Freeman-Browne 
described cerebral atrophy, enlargement of the lateral and 
third ventricles, thinning of the corpus callosum, cavum 
septum pellucidum with fenestrations, cerebellar scarring, 
and argyrophilic neurofibrillary degeneration using cresyl 
violet and Von Braunmühl’s silver stains [5]. Subsequent 
re-examination of Corsellis’ original series of boxers and 
additional cases using beta-amyloid (Aβ) immunohisto-
chemistry determined that 95 % of CTE cases showed 
widespread diffuse Aβ deposits [43, 46].
Over the following decades, it was recognized that the 
condition affected men and women with a broad range of 
exposure to brain trauma, including physical abuse [42], 
head-banging [13, 18], poorly controlled epilepsy, “dwarf-
throwing” [48], and rugby1 [13]. Eventually, the term 
“chronic traumatic encephalopathy” or “CTE”, introduced 
by Critchley in 1949 [8], became the preferred designation 
for the condition.
Coincident with the use of more refined methodol-
ogy, the early pathology of CTE was reported in several 
young subjects [13, 14, 18]. Hof reported a single case of 
repetitive head-banging in a young autistic patient with 
numerous perivascular clusters of thioflavin and Gallyas-
positive neurofibrillary tangles (NFTs) and neurites at the 
depths of the cerebral sulci and in the superficial layers of 
the inferior temporal, entorhinal and perirhinal cortices in 
the absence of Aβ plaques [18]. Hof and colleagues also 
quantitatively demonstrated the preferential distribution of 
the NFTs in superficial layers II and III in CTE, a lami-
nar predilection characteristic of two other environmen-
tally acquired tauopathies, post-encephalitic parkinsonism 
and Guamanian parkinsonism dementia complex (GPDC), 
but not found in Alzheimer’s disease (AD) [19]. Geddes 
and colleagues further described argyrophilic, hyperphos-
phorylated tau (p-tau) immunopositive neocortical NFTs 
and neuropil threads strikingly arranged in groups around 
small cortical blood vessels, in addition to diffuse granular 
cytoplasmic immunopositivity in some neurons [13]. Ged-
des also noted that the topography of the p-tau pathology 
principally involved the depths of sulci and that there was 
no Aß deposition in the 5 young cases that formed the basis 
of their manuscript [13].
Omalu and colleagues were the first to report CTE in a 
professional American football player [38, 39] and a pro-
fessional wrestler [37]. Recent neuropathological studies 
have identified CTE in athletes who played soccer, base-
ball, ice hockey and rugby, as well as in military person-
nel exposed to explosive blast [15, 29, 31, 32, 36, 45]. 
P-tau pathology, with some features of CTE, has also been 
1 Although often referred to as a soccer player, the young subject 
with CTE described by Geddes et al. 1999 as the “keen amateur foot-
baller who frequently “headed” the ball while playing” [13], was an 
amateur rugby player (personal communication, T. Revesz).
13 Department of Neuropathology, University of Glasgow 
Institute of Neuroscience and Psychology and Queen 
Elizabeth University Hospital, 1345 Govan Road, 
Glasgow G51 4TF, UK
14 Department of Biostatistics, Boston University School 
of Public Health, 801 Massachusetts Avenue, Boston MA, 
02118, USA
15 Department of Pathology, Fishberg Department 
of Neuroscience, Friedman Brain Institute, Ronald M. Loeb 
Center for Alzheimer’s Disease, Icahn School of Medicine 
at Mount Sinai School, One Gustave L. Levy Place, New 
York, NY 10029, USA
16 Department of Rehabilitation Medicine, Icahn School 
of Medicine at Mount Sinai, 3 East 101st Street, New York, 
NY 10029, USA
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described following exposure to single moderate or severe 
traumatic brain injury, together with Aβ plaques [20, 44].
In 2013, McKee and colleagues described a spectrum of 
p-tau pathology in 68 male subjects with a history of expo-
sure to repetitive brain trauma with neuropathological evi-
dence of CTE, ranging in age from 17 to 98 years (mean 
59.5 years). In young subjects with the mildest forms of 
CTE, focal perivascular epicenters of NFTs and astrocytic 
tangles (ATs) were found clustered at the depths of the 
cortical sulci; in subjects with severe disease, a profound 
tauopathy involved widespread brain regions [32]. Other 
abnormalities encountered in advanced disease included 
abnormal deposits of phosphorylated TAR DNA-binding 
protein of 43 kDa (TDP-43) protein that occasionally co-
localized with p-tau, varying degrees of Aβ pathology, 
axonal dystrophy and neuroinflammation [30, 32]. Based 
on these findings, preliminary criteria for the neuropatho-
logical diagnosis of CTE were proposed, as follows:
1. Perivascular foci of p-tau immunoreactive NFTs and 
ATs in the neocortex
2. Irregular distribution of p-tau immunoreactive NFTs 
and ATs at the depths of cerebral sulci
3. NFTs in the cerebral cortex located preferentially in 
the superficial layers (often most pronounced in tem-
poral cortex)
4. Supportive, non-diagnostic features: Clusters of sub-
pial ATs in the cerebral cortex, most pronounced at 
the sulcal depths.
In March 2013, the National Institutes of Health (NIH), 
supported by the Foundation for NIH’s Sports Health 
Research Program with funding from the National Football 
League (NFL), launched a major effort to define the neu-
ropathological characteristics of CTE. Two projects were 
initiated on the neuropathology of CTE and the delayed 
effects of traumatic brain injury. One of the initial objec-
tives was to convene a consensus meeting to define the 
neuropathological criteria for the diagnosis of CTE. The 
primary objective for the first meeting was to determine 
whether CTE was a distinctive tauopathy that could be reli-
ably distinguished from other tauopathies using the prelim-
inary criteria. The study design was modeled after previous 
successful NIH-sponsored consensus conferences for other 
tauopathies, specifically progressive supranuclear palsy 
(PSP) and corticobasal degeneration (CBD) [10, 17, 25].
Materials and methods
Individuals not directly involved in the pathological eval-
uation (ACM, VEA, KFB, JFC) selected 25 cases of the 
various tauopathies. The selected cases were considered to 
be representative of the disease and of at least moderate 
disease severity. The cases included 10 recently acquired 
cases of suspected CTE that were donated as part of the 
NINDs-funded traumatic brain injury (TBI) brain bank at 
Boston University School of Medicine (BUSM), including 
7 cases with Aβ plaques and 3 cases without Aß plaques. 
Five cases of AD, Braak stage V-VI, 2 cases of PSP and 
2 cases of CBD were selected from the Alzheimer’s Dis-
ease Center (ADC) brain bank at BUSM. Two cases of 
GPDC and 2 cases of argyrophilic grain disease (AGD) 
were selected from the Alzheimer’s Disease Research 
Center (ADRC) brain bank at Mayo Clinic-Jacksonville, 
and 2 cases of primary age-related tauopathy (PART) were 
selected from the ADRC brain bank at Columbia Uni-
versity. Paraffin-embedded tissue blocks from 12 brain 
regions from each case were sent to the TBI Brain Bank 
at BUSM for uniform processing, staining and immuno-
histochemistry (IHC) (Table 1); 2 of the selected cases 
were missing the superior temporal block. Sections were 
stained with Luxol fast blue counterstained with hematox-
ylin and eosin (LHE) and Bielschowsky silver impregna-
tion; IHC was performed using anti-Aβ42 (Aß 1-42, EMD 
Millipore, 1:2000, pretreated with 88 % formic acid for 
2 min; or Aβ-4G8, Bio Legend, 1:100,000, pretreated with 
formic acid); anti-p-tau (AT8, Thermo Fisher Scientific/
Table 1  Brain regions evaluated in the case review
Digitized images of the following microscopic slides were provided 
to the evaluating neuropathologists on 25 cases of tauopathies includ-
ing AD, AGD, CBD, CTE, GPDC, PART and PSP. The slides were all 
uniformly processed by a single laboratory
Aβ Beta-amyloid, AD Alzheimer’s disease, AGD Argyrophilic grain 
disease, BA Brodmann area, BIEL Bielschowsky’s silver method, 
CTE Chronic traumatic encephalopathy, GPDC Guamanian Parkin-
son’s dementia complex, LHE Luxol fast blue, counterstained with 
hematoxylin and eosin, PART Primary age-related tauopathy, PSP 
Progressive supranuclear palsy
Brain region Stains/IHC
LHE AT8 Aβ42 TDP43 BIEL
Superior frontal (BA 8, 9) X X
Dorsolateral superior frontal (BA 
45, 46)
X X X
Caudate nucleus, nucleus accum-
bens, putamen
X X
Temporal pole (BA 38) X X
Superior temporal gyrus (BA 20, 
21,22)
X X X
Amygdala, with entorhinal cortex 
(BA 28)
X X
Hippocampus and lateral genicu-
late nucleus
X X X X X
Thalamus and mammillary body X X
Cerebellum with dentate nucleus X X
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Pierce, 1:2000, pretreated with formic acid) and anti-p-
TDP-43 (Anti-TDP-43, phospho, 1:2000, pretreated with 
formic acid) for a total of 27 slides per case (25 slides in 
2 cases). An individual blinded to the origin and identity 
of the cases (KFB) scanned the 671 glass pathology slides 
into digital images at the Mayo Clinic Jacksonville using 
an Aperio scanner (Leica Biosystems, Buffalo Grove, IL). 
The digitized images were organized into folders labeled 
with only the case number (#1-25), brain region, stain and 
IHC and provided to the evaluating neuropathologists on 
portable hard drives as well as on an online slide-hosting 
website (Leica Biosystems-Aperio). No clinical or demo-
graphic information was provided to the evaluating neu-
ropathologists—including no information regarding the 
subjects’ age, gender, clinical symptoms, diagnosis or 
athletic exposure. No information was supplied regard-
ing the gross neuropathological features of the brains. The 
neuropathologists were given a tauopathy criteria guide 
that provided the provisional criteria for CTE [32] as well 
as published criteria for the other tauopathies (See sup-
plementary material for full tauopathy criteria guide) [4, 
7, 11, 21, 25, 34, 40, 47]. Although the neuropathologists 
knew that the selected cases represented presumptive CTE, 
AD, PSP, CBD, AGD, PART, and GPDC, they did not 
know how many cases representing each diagnosis were to 
be evaluated.
Seven neuropathologists with experience in neurodegen-
erative diseases, including the tauopathies, participated in 
the evaluation of the digitized images (NJC, DWD, RDF, 
CDK, DPP, TDS, JPV). The neuropathologists evaluated 
the cases independently, at their own pace, and completed 
an evaluation form that included the pathological diagnosis 
and a 4-scale level of certainty (1, unsure; 2, possible; 3, 
probable; 4, definite). After the initial evaluations were sent 
to BUSM for analysis, the evaluator was provided the gross 
neuropathological findings and clinical summaries for each 
case, and asked to reevaluate the diagnosis and provide a 
second level of conviction. The results of all evaluations 
were analyzed prior to the face-to-face meeting held on 
February 25–26, 2015.
Statistical analysis
To evaluate the agreement among the neuropathologists 
who reviewed the cases, two sets of Cohen’s kappa statis-
tics were calculated. The first kappa coefficient measured 
the agreement among the overall neuropathological diagno-
ses; the second kappa coefficient measured the agreement 
among neuropathologists regarding the specific diagnosis 
of CTE. The overall kappa coefficient combines the neu-
ropathologist-level estimates of kappa into an overall esti-
mate of the common agreement. Kappa values of 0.81–1.0 
indicate very good agreement, kappa values of 0.61–0.80 
show good agreement, while kappa values of 0.41–0.60 
indicate moderate agreement [12]. All statistical analyses 
were done using SAS 9.4 (SAS Institute Inc., Cary, North 
Carolina, USA) software.
At the face-to-face consensus meeting, a larger panel 
that included ACM2, WS,2 IL, WAG and members of the 
NINDs TBI/CTE group reviewed the results of the neuro-
pathological evaluations, digitized images and glass pathol-
ogy slides and discussed the cases as a group. Discussions 
led to refinements in the neuropathological criteria for 
CTE, as well as “best practice” recommendations for neu-
ropathologists examining brains for evidence of CTE.
Results
There was good agreement regarding the overall neuro-
pathological diagnosis of all 25 cases (Cohen’s kappa, 
0.67), and even better agreement regarding the specific 
diagnosis of CTE (Cohen’s kappa, 0.78), using the pro-
posed criteria. In evaluating the 10 cases submitted with the 
presumptive diagnosis of CTE (Supplementary Table 1), 
64 of the 70 reviewers responses (91.4 %) indicated CTE 
as the diagnosis. There was a significant decrease of errors 
that paralleled the sequence of cases evaluated. The log of 
the expected errors significantly decreased by 0.43 for each 
case of CTE reviewed (p value = 0.024). There were com-
mon additions to the CTE diagnosis, including “Changes 
of Alzheimer’s disease” (ADC) and AD in the cases with 
Aß plaques (cases #4–10). Other co-morbid diagnoses 
included hippocampal sclerosis (HS), AGD and PART. In 
the 15 other tauopathy cases (cases submitted for review 
with diagnoses other than CTE) (Supplementary Table 2), 
the reviewers generally agreed with the submission diagno-
ses of AD (97.1 % of responses), CBD (92.8 %), and PART 
(78.5 %); however, there were frequent discrepancies in 
cases with the presumptive diagnoses of PSP, AGD and 
GPDC (Supplementary Table 2). The evaluators reported 
a significantly increased degree of certainty (t test = 4.36, 
p value <0.001) in the diagnosis of CTE from an overall 
mean of 3.1 in a 4-point scale of conviction (1, unsure; 2, 
possible; 3, probable; 4, definite) to a mean of 3.7 after the 
gross neuropathological features and clinical features of 
the cases were provided to the evaluator. Three initial diag-
noses of non-CTE were changed to CTE and 9 diagnoses 
of co-morbid CTE in non-CTE cases were changed to no 
CTE after revealing the clinical and gross neuropathologi-
cal features.
2 Neuropathologist present at the face-to-face panel discussion, but 
did not participate in the slide evaluations.
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Diagnostic neuropathological features of CTE
The group defined a neuropathological lesion specific to 
CTE that distinguished the disorder from other tauopa-
thies. The pathognomonic lesion of CTE consists of p-tau 
aggregates in neurons, astrocytes, and cell processes 
around small vessels in an irregular pattern at the depths 
of the cortical sulci (Figs. 1, 2; Table 2). The group also 
noted that the distinctively irregular spatial pattern of 
p-tau in CTE was often visible with low-power inspec-
tion (Fig. 1). Although other abnormalities in p-tau were 
also found, especially in the more severely affected 
brains, the pathognomonic lesion was distinct and not 
found in the other degenerative tauopathies (Fig. 2). In 
addition, the group observed frequent evidence of other 
pathologies in CTE, including TDP-43-immunoreactive 
neuronal cytoplasmic inclusions, Aβ plaques and amyloid 
angiopathy, and hippocampal neurofibrillary degenera-
tion, including extracellular tangles best seen with silver 
stains.
Supportive neuropathological features of CTE
The group defined supportive pathological features for 
CTE. These features were commonly found in the CTE 
cases in addition to the required criteria, but were not con-
sidered diagnostic in isolation (Table 2).
Exclusions to the sole diagnosis of CTE
The presence of changes compatible with the diagnosis 
of another neurodegenerative disease excludes CTE as a 
Fig. 1  Low magnification inspection of p-tau-stained slides often revealed the irregular spatial pattern of CTE pathology. AT8-stained slides of 
cerebral cortex in 3 cases of CTE showing irregular patches of p-tau pathology most dense at the depths of the sulci
Fig. 2  The microscopic features of the pathognomonic lesion of 
CTE. The pathognomonic feature of CTE is a perivascular accumula-
tion of p-tau aggregates in neurons, astrocytes and cell processes in 
an irregular spatial pattern in the cerebral cortex and found prefer-
entially at the depths of the sulci. a A large perivascular p-tau lesion 
is found at the sulcal depths in a subject with CTE. b–f Multiple 
perivascular foci are often found in the cortex in CTE. g The p-tau 
aggregates in CTE include strikingly rounded structures in the neu-
ropil that often are most dense in the areas surrounding the vessel. h 
The rounded p-tau immunoreactive cell processes are more densely 
distributed than those found in argyrophilic grain disease. All sec-
tions immunostained for AT8, bars indicate 100 µm, except in g and 
h where the small bars indicate 10 µm
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single diagnosis, and indicates the presence of co-morbid 
pathology. These features include CA1-predominant neu-
rofibrillary degeneration in the hippocampus in association 
with Aβ plaques consistent with AD [34]; prominent cer-
ebellar dentate nucleus cell loss, coiled bodies in oligoden-
droglia, and tufted astrocytes as seen in PSP [25]; severe 
involvement of the striatum and pallidum with extensive 
astrocytic plaques in cortical and subcortical structures as 
seen in CBD [21] or globular astrocytic inclusions of glob-
ular glial tauopathy [1].
Discussion
The consensus panel of neuropathologists found that 
the p-tau pathology of CTE is clearly distinct from other 
tauopathies. The panel concluded that there is a pathogno-
monic lesion of CTE that consists of an accumulation of 
abnormal tau in neurons and astroglia distributed around 
small blood vessels at the depths of sulci in the cortex in 
an irregular spatial pattern. Other supportive features of 
CTE include abnormal p-tau immunoreactive pretangles 
Fig. 3  Hippocampal pathology in CTE. Examples of hippocampal 
pathology in 2 cases of CTE of moderate severity. In example 1 (a–f), 
there is a mild hippocampal atrophy, b mild neuronal loss in CA1, 
c sparse NFTs in CA1, Bielschowsky silver stain, d sparse NFTs in 
CA1, AT8 immunostain, e moderate numbers of diffusely immunopo-
sitive AT8 stained neurons in CA4, and f occasional AT8 immunopo-
sitive NFTs in the dentate gyrus. In example 2 (g–l), there is g more 
severe hippocampal atrophy, h clear neuronal loss in CA1, i moder-
ate density of NFTs in CA1, Bielschowsky silver stain, j moderate 
density of NFTs in CA1, AT8 immunostain, k high numbers of AT8-
stained neurons and NFTs in CA4, and l moderate numbers of AT8 
immunopositive NFTs in the dentate gyrus. Bars indicate 100 µm
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Fig. 4  pTDP-43 pathology in CTE. a pTDP-43 neuronal inclusions 
in the amygdala. b p-TDP-43 inclusions and dot-like neurites in CA1. 
c p-TDP-43 dot-like neurites in entorhinal cortex. d pTDP-43 inclu-
sions and dot-like neurites in the dentate granule cell layer. All sec-
tions immunostained for p-TDP-43, bars indicate 100 µm
Table 2  Preliminary NINDS criteria for the pathological diagnosis of CTE
Required for diagnosis of CTE
1. The pathognomonic lesion consists of p-tau aggregates in neurons, astrocytes, and cell processes around small vessels in an irregular pattern 
at the depths of the cortical sulci
Supportive neuropathological features of CTE
p-Tau-related pathologies:
 1. Abnormal p-tau immunoreactive pretangles and NFTs preferentially affecting superficial layers (layers II–III), in contrast to layers III and 
V as in AD
 2. In the hippocampus, pretangles, NFTs or extracellular tangles preferentially affecting CA2 and pretangles and prominent proximal dendritic 
swellings in CA4. These regional p-tau pathologies differ from the preferential involvement of CA1 and subiculum found in AD (Fig. 3)
 3. Abnormal p-tau immunoreactive neuronal and astrocytic aggregates in subcortical nuclei, including the mammillary bodies and other hypo-
thalamic nuclei, amygdala, nucleus accumbens, thalamus, midbrain tegmentum, and isodendritic core (nucleus basalis of Meynert, raphe 
nuclei, substantia nigra and locus coeruleus)
 4. p-Tau immunoreactive thorny astrocytes at the glial limitans most commonly found in the subpial and periventricular regions
 5. p-Tau immunoreactive large grain-like and dot-like structures (in addition to some threadlike neurites) (Fig. 2h)
Non-p-tau-related pathologies:
 1. Macroscopic features: disproportionate dilatation of the third ventricle, septal abnormalities, mammillary body atrophy, and contusions or 
other signs of previous traumatic injury
 2. TDP-43 immunoreactive neuronal cytoplasmic inclusions and dot-like structures in the hippocampus, anteromedial temporal cortex and 
amygdala (Fig. 4)
Age-related p-tau astrogliopathy that may be present; non-diagnostic and non-supportive [22]
 1. Patches of thorn-shaped astrocytes in subcortical white matter
 2. Subependymal, periventricular, and perivascular thorn-shaped astrocytes in the mediobasal regions
 3. Thorn-shaped astrocytes in amygdala or hippocampus [22]
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and NFTs preferentially affecting superficial layers (layers 
II–III), pretangles, NFTs or extracellular tangles primarily 
in CA2 and CA4 of the hippocampus, NFTs in subcortical 
nuclei, including the mammillary bodies and other hypo-
thalamic nuclei, amygdala, nucleus accumbens, thalamus, 
midbrain tegmentum, isodendritic core (nucleus basalis 
of Meynert, raphe nuclei, substantia nigra and locus coer-
uleus), p-tau immunoreactive thorned astrocytes at the glial 
limitans in the subpial and periventricular regions, p-tau 
immunoreactive large grain-like and dot-like structures, 
and TDP-43 immunoreactive neuronal cytoplasmic inclu-
sions and dot-like structures in the hippocampus, anterome-
dial temporal cortex and amygdala. While this was only the 
first meeting to address the neuropathological diagnosis of 
CTE, and more research is needed to determine the nature 
and degree of brain injury necessary to cause this neurode-
generation, the panel members also noted that the pathog-
nomonic lesion of CTE has, thus far, only been found in 
individuals who were exposed to brain trauma, typically 
multiple episodes.
The panel also determined that the pathognomonic 
lesion of CTE is distinct from age-related tau astrogliop-
athy (ARTAG), a morphological spectrum of astroglial 
pathology detected by p-tau immunohistochemistry that 
may coexist in the same brain with other disorders and is of 
unclear etiology (Fig. 5). P-tau-immunoreactive astrocytes 
in ARTAG include thorn-shaped astrocytes in the subpial, 
subependymal, and perivascular regions of the white and 
gray matter (Kovacs, in press). Changes of ARTAG may 
be present in CTE, but in isolation, are non-specific and 
non-diagnostic.
Although 9 of the 10 subjects diagnosed with CTE in 
this study were former American football players and only 
one was a former professional boxer, previous data has 
shown that the pathological features of CTE associated 
with boxing (often referred to as “dementia pugilistica”) 
are similar to the pathological features of CTE associated 
with football [28, 32]. Furthermore, the cortical areas most 
likely to show early focal CTE pathology in boxers are 
similar to American football players. While initial reports 
of boxers with CTE described cerebellar scarring, atrophy 
and loss of Purkinje cells [5], recent studies of pugilists 
find that cerebellar pathology is rare aside from p-tau NFTs 
and neurites in the dentate nucleus, Purkinje cells and roof 
of the 4th ventricle [28, 32].
Future directions
Using criteria from this consensus meeting, Bieniek and 
colleagues reviewed the clinical records and brains of 1721 
cases donated to the Mayo Clinic Brain Bank over the 
past 18 years, and found CTE pathology in 32 % of con-
tact sport athletes [2]. No cases of CTE were found in 162 
control brains without a history of brain trauma or in 33 
Fig. 5  Age-related p-tau astrogliopathy that may be present. a and 
b. Subpial p-tau immunopositive astrocytes may be found at the glial 
limitans in the sulcal depths but are non-specific and non-diagnostic 
for CTE (asterisks). c However, p-tau immunopositive subpial astro-
cytes accompanied by perivascular foci of p-tau positive neurons and 
astrocytes (arrowhead) at the depths of the sulci are diagnostic for 
CTE. d and e p-Tau immunopositive astrocytes surrounding small 
venules in the deep white matter of the temporal lobe are not diag-
nostic for CTE and are often found in association with aging [22]. 
f p-Tau positive astrocytes may also be found in the crests of the 
white matter of the frontal and temporal lobes with aging and other 
conditions that are not diagnostic for CTE [22]. All sections immu-
nostained for AT8, bars indicate 100 µm
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cases with a history of a single traumatic brain injury. Of 
the 21 with CTE pathology, 19 had participated in football 
or boxing, and many were multiple sport athletes includ-
ing rugby, wrestling, basketball, and baseball. One athlete 
played only baseball, and another athlete only played bas-
ketball. Similarly, Ling and colleagues screened 268 cases 
of neurodegenerative disease and controls in the Queen 
Square Brain Bank for Neurological Disorders using the 
preliminary McKee criteria [32] and found changes of CTE 
in 11.9 % of neurodegenerative disorders and 12.8 % of 
elderly controls. Of the cases with changes of CTE, 93.8 % 
had a history of TBIs, 34 % had participated in high-risk 
sports including rugby, soccer, cricket, lacrosse, judo and 
squash, and 18.8 % were military veterans [24]. However, 
it is unclear if all the cases with CTE changes described by 
Ling and colleagues would have met strict criteria for CTE 
using these newly defined NINDS guidelines. Furthermore, 
the relationship between non-diagnostic, non-specific astro-
cytic p-tau pathology and a history of traumatic exposure 
remains to be determined (Kovacs, in press).
At the present time, CTE remains a diagnosis that can 
only be made definitively upon neuropathological exami-
nation of the brain. Because the pathological diagnosis 
requires p-tau immunohistochemistry and the lesions are 
irregularly distributed, the detection of CTE in autopsy 
cohorts may require additional sampling compared to rou-
tine practices. The consensus panel’s minimum recom-
mended sampling for CTE is found in Table 3. Sampling 
follows the protocol recommended by Alzheimer Disease 
Centers (National Institute on Aging-Alzheimer’s Associa-
tion (NIA-AA) [34]) with the further recommendation that 
all cortical sections be taken to include the region at the 
depths of the cortical sulci. This has been shown in pilot 
studies to detect 80 % of CTE cases; however, 20 % of 
CTE cases, all early stage, would be missed by this sam-
pling scheme [9]. Of the NIA-AA sampling guidelines, the 
following blocks are most valuable for detecting CTE: sul-
cal depths of the superior and middle frontal gyrus, supe-
rior and middle temporal gyrus and inferior parietal gyrus 
(Fig. 6). Of note, the Bielschowsky silver stain does not 
always detect the diagnostically significant focal perivascu-
lar cortical tau lesions, and the panel recommended p-tau 
immunohistochemistry for the diagnosis of CTE using AT8 
immunostaining or equivalent p-tau antibody (CP-13 or 
PHF-1). The question of how extensive the sampling must 
be to “rule out” CTE was discussed, but no data were avail-
able to make this determination.
These criteria are the beginning of the process to fully 
characterize the pathology of CTE, and this is only the first 
of a series of consensus conferences on the subject funded 
by the U01 NINDS research initiative. Many important ques-
tions were not addressed in this first consensus panel, includ-
ing the degree of neuronal cell loss, gliosis, inflammation, 
and hemosiderin deposition, and the diagnosis of CTE in 
the presence of comorbid pathologies, including AD. Future 
directions will include further validation of the neuropatho-
logical criteria for CTE, including staging of the severity of 
p-tau pathology and characterization of early disease. More 
pathological characterization will also be necessary to deline-
ate the involvement of the other subcortical regions, including 
amygdala, globus pallidus, subthalamic nucleus, accumbens, 
neostriatum, thalamus, midbrain, cerebellum, spinal cord and 
white matter. It will also be important to determine the differ-
ential hippocampal p-tau pathology in CTE compared to AD, 
whether the TDP-43 pathology is distinctive for CTE and the 
contribution of hippocampal sclerosis and TDP-43 deposition 
to the clinical and pathological features. Population isolates 
Table 3  Recommended brain regions to be sampled and evaluated
In addition to the NIA-AA recommended regions for the evaluation 
of Alzheimer’s disease (AD) neuropathologic change and Lewy body 
disease (LBD) [34], we recommend wider p-tau screening to capture 
CTE and other tauopathies. In addition, if there is a high index of sus-
picion of CTE, we recommend taking extra sections of frontal and 
temporal cortices, and hypothalamus including the mammillary body
Bilateral representative sections from each region are recommended 
if both cerebral hemispheres are available for microscopic analysis
* Most valuable for detecting CTE neuropathology
a AT8 or equivalent Tau (CP-13 or PHF-1) on all cortical sections, if 
positive: stain other areas and possibly sample additional areasd. We 
do not recommend thioflavin or silver stains for the detection of CTE 
lesions
b TDP-43: amygdala and hippocampus, if positive then temporal pole 
and frontal cortex
c Aβ: middle frontal gyrus, inferior parietal lobule and hippocampus 
and entorhinal cortex; if positive wider sampling is recommended
d If there is a high index of suspicion consider taking extra sections, 
specifically superior frontal gyrus, temporal pole, and hypothalamus 
including mammillary body
Region CTE
Middle frontal gyrus* pTaua pTDP-43 Aβc
Superior and middle temporal gyri* pTaua
Inferior parietal lobule* pTaua Aβc
Hippocampus and entorhinal cortex pTau pTDP-43b Aβc
Amygdala pTau pTDP-43b
Thalamus pTau
Basal ganglia with basal nucleus of Meynert pTau
Midbrain including substantia nigra pTau
Pons including locus coeruleus pTau
Medulla including dorsal motor nucleus of 
vagus
pTau
Cerebellar cortex and dentate nucleus pTau
Additional sections if high suspicion
 Superior frontal gyrus pTaud
 Temporal pole pTaud pTDP-43
 Hypothalamus including mammillary body pTaud
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that develop unusual p-tau pathologies will need to be distin-
guished from CTE pathology in addition to Guam, such as 
the Kii peninsula of Japan [23]. In addition, the contributions 
of other proteinopathies, including β-amyloidosis (diffuse and 
dense core Aβ plaques and amyloid angiopathy) and alpha-
synuclein will be important to determine. Similarly, the role 
of microvascular pathology, iron deposition, axonal injury, 
neuroinflammation and astrocytosis to the pathogenesis of 
CTE pathology needs resolution.
Future investigation will be needed to understand the rela-
tionship of the pathology to the clinical symptoms, genetics, 
neuroimaging and other biomarkers (including p-tau posi-
tron emission tomography (PET) imaging and cerebrospinal 
fluid (CSF) and blood biomarkers), metabolomics, proteom-
ics, and epigenetics. It will also be important to determine 
whether specific “tau strains” are involved in the develop-
ment of CTE. Furthermore, more information is needed 
regarding the frequency, severity, and nature of the traumatic 
exposures, length of survival after trauma, as well as factors 
such as the age at first and last exposure to trauma, and the 
effects of military compared to civilian brain trauma.
The limitations of the present study include the rela-
tively small sample set, the use of digitized images, the 
selection of suspected CTE cases by a single source, the 
use of representative cases of moderate-to-late stage sever-
ity of CTE, and presence of some age-related co-morbid-
ities. However, these limitations are offset by the fact that 
all evaluating neuropathologists were evaluating the exact 
same digital images, the cases were all uniformly prepared 
by a central laboratory, and the evaluation was performed 
blinded to all clinical or demographical data and gross neu-
ropathological findings. Other limitations to the present 
study include the lack of data regarding TBI history in the 
non-CTE cases under evaluation. Future studies are being 
designed to specifically address the contribution of TBI at 
all levels of severity to neurodegenerative pathologies.
Conclusion
A consensus panel of 7 neuropathologists blinded to all 
clinical conditions and demographics evaluated the identical 
digitized images of 25 cases representing various tauopa-
thies and concluded that the pathology of CTE is distinct 
from other tauopathies. In addition, the panel described the 
pathognomonic lesion of CTE as an accumulation of abnor-
mal tau in neurons and astroglia distributed perivascularly 
at the depths of sulci in the isocortex in an irregular pattern. 
Future consensus meetings will address validation of the cri-
teria among a wider group of neuropathologists using cases 
submitted from multiple sources. In addition, future meet-
ings will address the identification of comorbid CTE when 
other neurodegenerative diseases and other diseases are pre-
sent. Furthermore, additional research will be necessary to 
determine the contribution of p-tau and other pathologies to 
the development of clinical symptoms of CTE.
Fig. 6  Minimum recommended brain regions for evaluation for CTE. 
The following sections from the NIA-AA blocking scheme are rec-
ommended for p-tau immunostaining in evaluation for CTE (blue rec-
tangles). In the cortical sections (blocks 1–5, 12, 13), the depths of 
the cortical sulci should be included in the section. 1 Middle frontal 
gyrus, 2 superior and middle temporal gyri, 3 inferior parietal lobule, 
4 hippocampus, 5 amygdala and entorhinal cortex, 6 basal ganglia at 
level of anterior commissure with basal nucleus of Meynert, 7 thala-
mus, 8 midbrain with substantia nigra, 9 pons with locus coeruleus, 
10 medulla oblongata, 11 cerebellar cortex and dentate nucleus; addi-
tional sections if high suspicion of CTE (red rectangles): 12 superior 
frontal gyrus, 13 temporal pole, 14 hypothalamus and mammillary 
body
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The incidence and prevalence of CTE remain unknown 
and will likely require methods of in vivo detection and 
diagnosis to make a clear determination. This first con-
sensus conference on the pathological criteria for CTE 
represents the first step along the path to standardizing 
the neuropathology of CTE and paving the way for future 
determinations of specific clinical symptomatology and 
refinements in clinical diagnosis.
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